Related Experiment Video
Updated: Aug 10, 2026
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
[Biochemical markers for Alzheimer disease]
Justyna Maria Czarna1, Gunhild Waldemar, Niels H H Heegaard
1Statens Serum Institut, Autoimmunafdelingen, og H:S Rigshospitalet, Hukommelsesklinikken, Neurologisk Afdeling.
Ugeskrift for Laeger
|March 9, 2006
Summary
Alzheimer's disease (AD) diagnosis is challenging. Cerebrospinal fluid (CSF) biomarkers, specifically total tau (t-tau) and hyperphosphorylated tau (p-tau), show promise for differentiating AD from other dementias.
Area of Science:
- Neuroscience
- Biomarker Research
- Dementia Studies
Context:
- Alzheimer's disease (AD) affects approximately 40,000 individuals in Denmark, presenting a significant public health challenge.
- Current diagnostic methods for AD are often invasive or only definitive post-mortem, hindering early intervention.
- Existing symptomatic treatments offer temporary relief but do not halt disease progression.
Purpose:
- To investigate the utility of cerebrospinal fluid (CSF) biomarkers in differentiating Alzheimer's disease (AD) from normal aging and other forms of dementia.
- To evaluate the diagnostic value of amyloid-beta 1-42 (Abeta1-42), total tau (t-tau), and hyperphosphorylated tau (p-tau) in CSF samples.
- To assess the sensitivity and specificity of these CSF biomarkers for early and accurate AD diagnosis.
Summary:
- Cerebrospinal fluid (CSF) analysis offers a potential avenue for diagnosing Alzheimer's disease (AD).
- While decreased amyloid-beta 1-42 (Abeta1-42) levels in CSF lack independent diagnostic value for AD, elevated levels of total tau (t-tau) and hyperphosphorylated tau (p-tau) demonstrate significant potential.
- The combination of t-tau and p-tau in CSF provides enhanced specificity and reasonable sensitivity for differentiating AD from other neurodegenerative conditions.
Impact:
- Improved diagnostic accuracy for Alzheimer's disease (AD), enabling earlier and more targeted treatment strategies.
- Potential for routine CSF biomarker analysis to become a standard component of dementia diagnostics.
- Facilitation of clinical trials and research by providing more reliable patient stratification based on AD biomarkers.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...